FDA leaders worry agency will lose out on talent in gene therapy, cancer fields

Food and Drug Administration leaders are concerned the agency won't be able to recruit and retain sufficient numbers of experts in fields that have undergone rapid scientific advances, such as cell and gene therapy or oncology.

In cell and gene therapy, the relevant FDA review unit aims to double in size over the next three to five years, competing with biopharmaceutical companies and venture firms for the same talent.